Clinical Trial Update: Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether nepafenac can reduce macular volume after epiretinal membrane surgery; the study by Alcon Research is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epiretinal Membrane

Drugs mentioned

• Nepafenac (nepafenac)

Snippet

Sponsor: Alcon Research | Conditions: Epiretinal Membrane | Phase 4 | Status: COMPLETED